DRDO's modern anti-Covid oral medication, 2-deoxy-D-glucose (2-DG), was previously allowed emergency practice permission by the Drug Controller General of India (DCGI) as an adjunct treatment in mild cases of COVID-19. The 2-DG drug is anticipated to assist hospitalized COVID-19 victims and diminish their additional oxygen dependency.

The anti-Covid oral drug has prevailed to be formulated by the Defence Research and Development Organisation's (DRDO's) governing laboratory- Institute of Nuclear Medicine & Allied Sciences (INMAS) in affiliation along with Dr. Reddy's Laboratories.

DRDO Project Director & Scientist of 2-DG, Dr. Sudhir Chandana clarified the procedure of how the drug was formulated. He declared that when the pandemic smashed India in April 2020, they found out that 2-DG halts the expansion of COVID-19 inside the body enclosures. 'After the conclusions, we inquired the DCGI for authorization to perform clinical prosecutions. In May 2020, we received approval for the clinical litigations. Over the end of October 2020, we possessed finalized the following stage of trials, and the outcomes were extremely reasonable. Using regular care, 2 DG will be further beneficial for the Covid-19 victims,' Chandana instructed.

An amount of 110 patients were a portion of the Phase-II clinical trials of DRDO's 2-DG drug. The outcomes exhibited that in periods of development of crucial indications of COVID-19 symptomatic victims there was a distinction of 2.5 days correlated to Standard of Care (SoC). Authorization for Phase - III clinical sessions were consented to in November 2020. These were performed in 27 COVID-19 hospitals circulate across various states. 'Clinical trial conclusions have demonstrated that this molecule assists in rapid healing of hospitalized patients and decreases accessory oxygen dependency,' an authorized DRDO declaration had clarified ahead.